Harwell Facility to Support Pandemic Preparedness
Based in Harwell, Oxfordshire, the Moderna Innovation Technology Centre (MITC) can begin with the commercial manufacturing of its mRNA vaccine for pandemic-preparedness.
This comes after an inspection confirming the plant's compliance with principles and guidelines of Good Manufacturing Practice (GMP) – allowing the site to be fully operational.
Moderna Advances UK mRNA Capabilities
“This significant achievement marks a major step forward in our mission to establish end-to-end mRNA manufacturing capabilities in the UK, and we are proud to have reached it in less than two years since breaking ground on the site,” said Darius Hughes, UK general manager of Moderna. “This important step brings the company closer to ensuring a reliable, onshore supply of mRNA vaccines within the UK.”
Government Collaboration for Future Health Response
The facility forms part of a ten-year partnership between the UK government and Moderna and is overseen by the UK Health Security Agency.
The collaboration plans to produce at least 250m doses during a future pandemic for the NHS and UK public.
Global Readiness with Strategic Sites
Moderna has sites also located in Canada and Australia that have been strategically located to allow the quick rollout of vaccines when needed.
